Thermo Showcase Advanced Proteomics Research Portfolio at HUPO 2016
Product News Sep 20, 2016
The featured technologies will be presented at the 15th Human Proteome Organization (HUPO) World Congress, September 18-22, Taipei International Convention Center, in booths 13-15 and 19-21.
“The field of proteomics is growing faster than ever, with capabilities extending to personalized medicine applications,” said Ken Miller, vice president of research product marketing, life sciences mass spectrometry, Thermo Fisher Scientific. “Our customers continue to push the boundaries of discovery in proteomics. At this conference, customers are presenting their methods to detect and quantify thousands of proteins in large sample sets to discover disease biomarkers, profile samples for personalized medicine databases and to unravel complex disease mechanisms.”
Thermo Fisher highlights at HUPO 2016 include:
• On display, Thermo Scientific Orbitrap-based MS systems offering advanced proteome profiling and structure analysis capabilities. The Q Exactive Hybrid Quadrupole-Orbitrap mass spectrometer and Thermo Scientific Orbitrap Fusion Lumos Tribrid mass spectrometer systems represent the ultimate level in performance in terms of precise, accurate detection and quantitation of proteins using label-free (LFQ), data independent (DIA) and tandem mass tag (TMT).
• The new Thermo Scientific KingFisher Presto sample purification system, designed to automate the isolation of targeted nucleic acids and proteins for high-throughput laboratories. The new system provides a robust solution for reliable purification of DNA, RNA and proteins, and its small footprint enables configurations for a range of applications.
• A novel antibody testing and verification methodology using immunoprecipitation-mass spectrometry (IP-MS), designed to help identify the best antibodies to study proteins. The new antibody verification pipeline will be leveraged with other existing platforms to test the specificity of antibodies in the Thermo Fisher portfolio in accordance with the recently published guidelines in Nature Methods for antibody validation. The guidelines, developed to address an unmet need for antibody specificity, functionality and reproducibility, were developed by the International Working Group on Antibody Validation (IWGAV), an independent group of international scientists studying protein biology.
In addition, Thermo Fisher will host several workshops, including:
High-Throughput Multiplexed Quantitative Proteomics for Personalized Medicine Applications
Monday, September 19, 12:30-1:30pm, North Lounge 3F
In this session, Loïc Dayon from Nestlé Institute of Health Sciences, Switzerland, will discuss the clinical-scale discovery of proteomics in human bodily fluids via high-throughput quantitative pipelines for clinical research and biomarker discovery. Also in this seminar, Bernd Wollscheid from the Institute of Molecular Systems Biology, ETH Zurich, Switzerland, will give an overview of the Zurich-Cancer-Maps project, an initiative aimed to generate a searchable ‘Digital Biobank’ from clinical specimens. Wollscheid will also share details regarding the conversion of biopsy samples into digital protein profiles using data independent analysis (DIA) on Orbitrap mass spectrometers, and the potential use of these profiles for cancer research.
Sweet Revolution: Analytical Tools for the Characterization of Glycans and Glycoproteins
Monday, September 19, 12:30-1:30pm, Joy Lounge 4F
Sergey Vakhrushev from the Department of Cellular Molecular Medicine, University of Copenhagen, Denmark, will present discovery and application of simple cell glycoproteins, including how it can be applied for the analysis of human cell lines, body fluids and tissues. Additionally, Christopher Ashwood from Macquarie University, Sydney, Australia, will present the use of Trap-HCD methods for the detection of lower mass range glycan fragments, and the additional value provided by these for glycan characterization.
Defining Biological Phenotypes by Quantifying Small Molecular Changes
Tuesday, September 20, 12:30-1:30pm, VIP Room 4F
Jenny Van Eyk from Cedars-Sinai Medical Center, USA, will discuss a dual-labelling mass spectrometric approach to improve detection of post-translational cysteine modification by S-nitrosation. Also in this session, Daniel Lopez-Ferrer from Thermo Fisher will demonstrate how DDA mass spectrometric analysis outperforms DIA technology, and how DDA acquisition can be used to achieve high peptide quantification.